rabbit anti cxcr5  (Cell Signaling Technology Inc)


Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Cell Signaling Technology Inc rabbit anti cxcr5
    mRNA and protein expression of key genes and related receptors. (A) mRNA expression of CCL21, XCR1, CXCL13, CASR, and EDN1. (B) Protein expression of CCL21, CXCL13, and XCR1. (C) Protein expression of GPR174/CCR7 (the receptors of CCL21) and <t>CXCR5</t> (the receptors of CXCL13). n = 3–6. * p < 0.05, ** p < 0.01 vs. the sham group. I/R, ischemia reperfusion.
    Rabbit Anti Cxcr5, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti cxcr5/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti cxcr5 - by Bioz Stars, 2024-05
    93/100 stars

    Images

    1) Product Images from "Activation of CCL21-GPR174/CCR7 on cardiac fibroblasts underlies myocardial ischemia/reperfusion injury"

    Article Title: Activation of CCL21-GPR174/CCR7 on cardiac fibroblasts underlies myocardial ischemia/reperfusion injury

    Journal: Frontiers in Genetics

    doi: 10.3389/fgene.2022.946524

    mRNA and protein expression of key genes and related receptors. (A) mRNA expression of CCL21, XCR1, CXCL13, CASR, and EDN1. (B) Protein expression of CCL21, CXCL13, and XCR1. (C) Protein expression of GPR174/CCR7 (the receptors of CCL21) and CXCR5 (the receptors of CXCL13). n = 3–6. * p < 0.05, ** p < 0.01 vs. the sham group. I/R, ischemia reperfusion.
    Figure Legend Snippet: mRNA and protein expression of key genes and related receptors. (A) mRNA expression of CCL21, XCR1, CXCL13, CASR, and EDN1. (B) Protein expression of CCL21, CXCL13, and XCR1. (C) Protein expression of GPR174/CCR7 (the receptors of CCL21) and CXCR5 (the receptors of CXCL13). n = 3–6. * p < 0.05, ** p < 0.01 vs. the sham group. I/R, ischemia reperfusion.

    Techniques Used: Expressing

    72172s  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Cell Signaling Technology Inc 72172s

    72172s, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/72172s/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    72172s - by Bioz Stars, 2024-05
    93/100 stars

    Images

    1) Product Images from "Tertiary lymphoid structure and decreased CD8 + T cell infiltration in minimally invasive adenocarcinoma"

    Article Title: Tertiary lymphoid structure and decreased CD8 + T cell infiltration in minimally invasive adenocarcinoma

    Journal: iScience

    doi: 10.1016/j.isci.2022.103883


    Figure Legend Snippet:

    Techniques Used: Recombinant, Software

    rabbit anti cxcr5 monoclonal antibody  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Cell Signaling Technology Inc rabbit anti cxcr5 monoclonal antibody
    TLS formation in MIA tumors (A) The schema of TLS formation. The first stage is B & T cell aggregation. The second stage is follicle formation with T-zone and B-zone. The third stage is ectopic germinal center formation with formation with follicular dendritic cell in light-zone. (B) Hierarchical clustering of Z score normalized gene expression of B cell infiltration markers (CD19 and CD20), follicle phenotype markers <t>(CXCR5</t> and CXCL13), and lymphocyte homing signal markers (CCR7 and CCL19). Color of the top bar represents tumor (red) or adjacent normal (blue) tissue. Correlations between expression levels from these six TLS markers and immune cell abundance corrected by tumor purity are shown in the right bar. p Values are calculated using Spearman correlation; ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05; ns p > 0.05. (C) Typical observation field of MIA six-plex TLS panel staining. The merged-channel multispectral image was captured after 5-cycle TSA staining and DAPI counterstain, revealing a classic lymphoid structure residing in MIA stromal tissue. Single channels are shown for the area bounded by the white rectangle. Fake colors are assigned as DAPI: blue, CD8: yellow, CXCR5: pink, CD4: green, CD20: red, CD35: cyan. Tfh cells are highlighted with white arrows (lower right corner images). (D–G) Paired comparisons of CD20 + B cell density, CD4 + T cell density (E), CD35 + follicle dendritic cell density (F), and CD8 + T cell density (G) between non-follicle (Non-Fol) and TLS areas
    Rabbit Anti Cxcr5 Monoclonal Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti cxcr5 monoclonal antibody/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti cxcr5 monoclonal antibody - by Bioz Stars, 2024-05
    93/100 stars

    Images

    1) Product Images from "Tertiary lymphoid structure and decreased CD8 + T cell infiltration in minimally invasive adenocarcinoma"

    Article Title: Tertiary lymphoid structure and decreased CD8 + T cell infiltration in minimally invasive adenocarcinoma

    Journal: iScience

    doi: 10.1016/j.isci.2022.103883

    TLS formation in MIA tumors (A) The schema of TLS formation. The first stage is B & T cell aggregation. The second stage is follicle formation with T-zone and B-zone. The third stage is ectopic germinal center formation with formation with follicular dendritic cell in light-zone. (B) Hierarchical clustering of Z score normalized gene expression of B cell infiltration markers (CD19 and CD20), follicle phenotype markers (CXCR5 and CXCL13), and lymphocyte homing signal markers (CCR7 and CCL19). Color of the top bar represents tumor (red) or adjacent normal (blue) tissue. Correlations between expression levels from these six TLS markers and immune cell abundance corrected by tumor purity are shown in the right bar. p Values are calculated using Spearman correlation; ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05; ns p > 0.05. (C) Typical observation field of MIA six-plex TLS panel staining. The merged-channel multispectral image was captured after 5-cycle TSA staining and DAPI counterstain, revealing a classic lymphoid structure residing in MIA stromal tissue. Single channels are shown for the area bounded by the white rectangle. Fake colors are assigned as DAPI: blue, CD8: yellow, CXCR5: pink, CD4: green, CD20: red, CD35: cyan. Tfh cells are highlighted with white arrows (lower right corner images). (D–G) Paired comparisons of CD20 + B cell density, CD4 + T cell density (E), CD35 + follicle dendritic cell density (F), and CD8 + T cell density (G) between non-follicle (Non-Fol) and TLS areas
    Figure Legend Snippet: TLS formation in MIA tumors (A) The schema of TLS formation. The first stage is B & T cell aggregation. The second stage is follicle formation with T-zone and B-zone. The third stage is ectopic germinal center formation with formation with follicular dendritic cell in light-zone. (B) Hierarchical clustering of Z score normalized gene expression of B cell infiltration markers (CD19 and CD20), follicle phenotype markers (CXCR5 and CXCL13), and lymphocyte homing signal markers (CCR7 and CCL19). Color of the top bar represents tumor (red) or adjacent normal (blue) tissue. Correlations between expression levels from these six TLS markers and immune cell abundance corrected by tumor purity are shown in the right bar. p Values are calculated using Spearman correlation; ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05; ns p > 0.05. (C) Typical observation field of MIA six-plex TLS panel staining. The merged-channel multispectral image was captured after 5-cycle TSA staining and DAPI counterstain, revealing a classic lymphoid structure residing in MIA stromal tissue. Single channels are shown for the area bounded by the white rectangle. Fake colors are assigned as DAPI: blue, CD8: yellow, CXCR5: pink, CD4: green, CD20: red, CD35: cyan. Tfh cells are highlighted with white arrows (lower right corner images). (D–G) Paired comparisons of CD20 + B cell density, CD4 + T cell density (E), CD35 + follicle dendritic cell density (F), and CD8 + T cell density (G) between non-follicle (Non-Fol) and TLS areas

    Techniques Used: Expressing, Staining

    Treg recruitment as potential mechanism of decreased CD8 + T cell infiltration in tertiary lymphoid structures (A) Comparison of immune suppressive cell infiltration estimated from XCELL between MIA tumor and adjacent normal tissues. p values are calculated using Mann-Whitney U test; ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05; ns p > 0.05. (B) Plot of Tfr/Tfh marker ratio vs CD8 + T cell infiltration. FoxP3, PDCD1, and IL2RA are markers of Tfr cells, while BCL6, ICOS, and IL7R are markers of Tfh cells. See text. p values are calculated using Spearman correlation test; ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05; ns p > 0.05. (C) Typical observation field of MIA 7-plex panel staining for Tfr and Tfh. Merged multispectral image was captured after 6-cycle TSA staining and DAPI counterstain and reveals a mature TLS architecture. Single channels are shown for the area bounded by the white rectangle. Fake colors are assigned as DAPI: blue, CD8: yellow, CXCR5: pink, CD4: green, FOXP3: red, BCL6: cyan and CD3: orange. Sub-populations of CD4 + T cells are highlighted by arrows (Tfr: red, Treg: purple, Th: green and Tfh: cyan). (D) Paired comparison of CD8 + T cell density between non-follicle (Non-Fol) and TLS areas. (E) Paired comparison of ratio of regulatory T cells to helper T cells between TLS and non-follicle areas. (F) Comparison of CD8 + T cell density between groups with high and low Tfr/Tfh ratio
    Figure Legend Snippet: Treg recruitment as potential mechanism of decreased CD8 + T cell infiltration in tertiary lymphoid structures (A) Comparison of immune suppressive cell infiltration estimated from XCELL between MIA tumor and adjacent normal tissues. p values are calculated using Mann-Whitney U test; ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05; ns p > 0.05. (B) Plot of Tfr/Tfh marker ratio vs CD8 + T cell infiltration. FoxP3, PDCD1, and IL2RA are markers of Tfr cells, while BCL6, ICOS, and IL7R are markers of Tfh cells. See text. p values are calculated using Spearman correlation test; ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05; ns p > 0.05. (C) Typical observation field of MIA 7-plex panel staining for Tfr and Tfh. Merged multispectral image was captured after 6-cycle TSA staining and DAPI counterstain and reveals a mature TLS architecture. Single channels are shown for the area bounded by the white rectangle. Fake colors are assigned as DAPI: blue, CD8: yellow, CXCR5: pink, CD4: green, FOXP3: red, BCL6: cyan and CD3: orange. Sub-populations of CD4 + T cells are highlighted by arrows (Tfr: red, Treg: purple, Th: green and Tfh: cyan). (D) Paired comparison of CD8 + T cell density between non-follicle (Non-Fol) and TLS areas. (E) Paired comparison of ratio of regulatory T cells to helper T cells between TLS and non-follicle areas. (F) Comparison of CD8 + T cell density between groups with high and low Tfr/Tfh ratio

    Techniques Used: MANN-WHITNEY, Marker, Staining


    Figure Legend Snippet:

    Techniques Used: Recombinant, Software

    rabbit anti cxcr5  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Cell Signaling Technology Inc rabbit anti cxcr5
    qPCR and Immunohistochemical to detect the expression of <t>CXCR5</t> in ccRCC tissues. A TCGA database and our hospital database detect the relationship between CXCR5mRNA expression and ccRCC clinicopathological characteristics. B TCGA database and our hospital database to detect the relationship between CXCR5mRNA expression and ccRCC prognosis. C Immunohistochemical staining of CXCR5 protein in ccRCC tissues and adjacent tissues
    Rabbit Anti Cxcr5, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti cxcr5/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti cxcr5 - by Bioz Stars, 2024-05
    93/100 stars

    Images

    1) Product Images from "M2 macrophages secrete CXCL13 to promote renal cell carcinoma migration, invasion, and EMT"

    Article Title: M2 macrophages secrete CXCL13 to promote renal cell carcinoma migration, invasion, and EMT

    Journal: Cancer Cell International

    doi: 10.1186/s12935-021-02381-1

    qPCR and Immunohistochemical to detect the expression of CXCR5 in ccRCC tissues. A TCGA database and our hospital database detect the relationship between CXCR5mRNA expression and ccRCC clinicopathological characteristics. B TCGA database and our hospital database to detect the relationship between CXCR5mRNA expression and ccRCC prognosis. C Immunohistochemical staining of CXCR5 protein in ccRCC tissues and adjacent tissues
    Figure Legend Snippet: qPCR and Immunohistochemical to detect the expression of CXCR5 in ccRCC tissues. A TCGA database and our hospital database detect the relationship between CXCR5mRNA expression and ccRCC clinicopathological characteristics. B TCGA database and our hospital database to detect the relationship between CXCR5mRNA expression and ccRCC prognosis. C Immunohistochemical staining of CXCR5 protein in ccRCC tissues and adjacent tissues

    Techniques Used: Immunohistochemical staining, Expressing, Staining

    Correlation between  CXCR5  expression and clinical characteristics of ccRCC patients
    Figure Legend Snippet: Correlation between CXCR5 expression and clinical characteristics of ccRCC patients

    Techniques Used: Expressing

    cxcr5  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Cell Signaling Technology Inc cxcr5
    a The dot plot summarizing the cell–cell interactions among CD8-C2 (T RM -like), B, and CD4-C9 (T FH -like) cells by CellPhoneDB analysis. Only significant ligand–receptor interactions are presented here. The size of the circle indicates the statistical significance, and the color gradient indicates the mean expression value of gene pairs. b Representative multiplexed immunofluorescence (IF) of TLS-like lesion in EGFR-WT ( n = 14) (upper) (scale bar 100 μm: left, scale bars 50 μm: right magnified) and EGFR-MT ( n = 14) (lower) (scale bar 100 μm: left, scale bars 50 μm: right magnified) tumors. Summarized graph for the area of TLS-like lesions in EGFR-WT ( n = 5) and EGFR-MT ( n = 4) tumors for single-cell analysis (** p ≤ 0.005, two-sided test) (upper panel) and in EGFR-WT ( n = 9) and EGFR-MT ( n = 10) tumors from independent patients for validation (* p ≤ 0.05, two-sided test) (lower panel). c Representative multiplexed IF of CD4, CXCL13, CD103, CD8, <t>CXCR5,</t> and CD20 in tumor specimens from EGFR-WT ( n = 14) (left) (scale bar 100 μm) and EGFR-MT ( n = 14) (right) (scale bar 100 μm) patients. d Summarized graph for the numbers of each cell type in total TLS-like lesions in EGFR-WT ( n = 5) and EGFR-MT ( n = 4) patients. The number of CD4 + , CXCL13 + CD4 + T cells, CD8 + T cells, CD103 + CD8 + T cells are significantly higher in EGFR-WT than EGFR-MT (* p ≤ 0.05, ** p ≤ 0.005, two-sided test). e Summarized graph for the numbers of each cell type in total TLS-like lesions in EGFR-WT ( n = 9) and EGFR-MT ( n = 10) tumors from independent patients for validation. Consistently, the number of CD4 + , CXCL13 + CD4 + T cells, CD8 + T cells, CD103 + CD8 + T cells were significantly higher in EGFR-WT than EGFR-MT (** p ≤ 0.005, *** p ≤ 0.0005, two-sided test). f An illustrative summary of the proposed model for T FH –B–T RM lymphocyte cooperation in TLS for antitumor immunity in lung cancer. Data are represented as mean ± SEM. Source data are provided as a Source Data file.
    Cxcr5, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cxcr5/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cxcr5 - by Bioz Stars, 2024-05
    93/100 stars

    Images

    1) Product Images from "Dysregulation of T FH -B-T RM lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR -mutant lung cancer"

    Article Title: Dysregulation of T FH -B-T RM lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR -mutant lung cancer

    Journal: Nature Communications

    doi: 10.1038/s41467-021-26362-0

    a The dot plot summarizing the cell–cell interactions among CD8-C2 (T RM -like), B, and CD4-C9 (T FH -like) cells by CellPhoneDB analysis. Only significant ligand–receptor interactions are presented here. The size of the circle indicates the statistical significance, and the color gradient indicates the mean expression value of gene pairs. b Representative multiplexed immunofluorescence (IF) of TLS-like lesion in EGFR-WT ( n = 14) (upper) (scale bar 100 μm: left, scale bars 50 μm: right magnified) and EGFR-MT ( n = 14) (lower) (scale bar 100 μm: left, scale bars 50 μm: right magnified) tumors. Summarized graph for the area of TLS-like lesions in EGFR-WT ( n = 5) and EGFR-MT ( n = 4) tumors for single-cell analysis (** p ≤ 0.005, two-sided test) (upper panel) and in EGFR-WT ( n = 9) and EGFR-MT ( n = 10) tumors from independent patients for validation (* p ≤ 0.05, two-sided test) (lower panel). c Representative multiplexed IF of CD4, CXCL13, CD103, CD8, CXCR5, and CD20 in tumor specimens from EGFR-WT ( n = 14) (left) (scale bar 100 μm) and EGFR-MT ( n = 14) (right) (scale bar 100 μm) patients. d Summarized graph for the numbers of each cell type in total TLS-like lesions in EGFR-WT ( n = 5) and EGFR-MT ( n = 4) patients. The number of CD4 + , CXCL13 + CD4 + T cells, CD8 + T cells, CD103 + CD8 + T cells are significantly higher in EGFR-WT than EGFR-MT (* p ≤ 0.05, ** p ≤ 0.005, two-sided test). e Summarized graph for the numbers of each cell type in total TLS-like lesions in EGFR-WT ( n = 9) and EGFR-MT ( n = 10) tumors from independent patients for validation. Consistently, the number of CD4 + , CXCL13 + CD4 + T cells, CD8 + T cells, CD103 + CD8 + T cells were significantly higher in EGFR-WT than EGFR-MT (** p ≤ 0.005, *** p ≤ 0.0005, two-sided test). f An illustrative summary of the proposed model for T FH –B–T RM lymphocyte cooperation in TLS for antitumor immunity in lung cancer. Data are represented as mean ± SEM. Source data are provided as a Source Data file.
    Figure Legend Snippet: a The dot plot summarizing the cell–cell interactions among CD8-C2 (T RM -like), B, and CD4-C9 (T FH -like) cells by CellPhoneDB analysis. Only significant ligand–receptor interactions are presented here. The size of the circle indicates the statistical significance, and the color gradient indicates the mean expression value of gene pairs. b Representative multiplexed immunofluorescence (IF) of TLS-like lesion in EGFR-WT ( n = 14) (upper) (scale bar 100 μm: left, scale bars 50 μm: right magnified) and EGFR-MT ( n = 14) (lower) (scale bar 100 μm: left, scale bars 50 μm: right magnified) tumors. Summarized graph for the area of TLS-like lesions in EGFR-WT ( n = 5) and EGFR-MT ( n = 4) tumors for single-cell analysis (** p ≤ 0.005, two-sided test) (upper panel) and in EGFR-WT ( n = 9) and EGFR-MT ( n = 10) tumors from independent patients for validation (* p ≤ 0.05, two-sided test) (lower panel). c Representative multiplexed IF of CD4, CXCL13, CD103, CD8, CXCR5, and CD20 in tumor specimens from EGFR-WT ( n = 14) (left) (scale bar 100 μm) and EGFR-MT ( n = 14) (right) (scale bar 100 μm) patients. d Summarized graph for the numbers of each cell type in total TLS-like lesions in EGFR-WT ( n = 5) and EGFR-MT ( n = 4) patients. The number of CD4 + , CXCL13 + CD4 + T cells, CD8 + T cells, CD103 + CD8 + T cells are significantly higher in EGFR-WT than EGFR-MT (* p ≤ 0.05, ** p ≤ 0.005, two-sided test). e Summarized graph for the numbers of each cell type in total TLS-like lesions in EGFR-WT ( n = 9) and EGFR-MT ( n = 10) tumors from independent patients for validation. Consistently, the number of CD4 + , CXCL13 + CD4 + T cells, CD8 + T cells, CD103 + CD8 + T cells were significantly higher in EGFR-WT than EGFR-MT (** p ≤ 0.005, *** p ≤ 0.0005, two-sided test). f An illustrative summary of the proposed model for T FH –B–T RM lymphocyte cooperation in TLS for antitumor immunity in lung cancer. Data are represented as mean ± SEM. Source data are provided as a Source Data file.

    Techniques Used: Expressing, Immunofluorescence, Single-cell Analysis

    rabbit anti cxcr5  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Cell Signaling Technology Inc rabbit anti cxcr5
    Rabbit Anti Cxcr5, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti cxcr5/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti cxcr5 - by Bioz Stars, 2024-05
    93/100 stars

    Images

    cxcr5  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Cell Signaling Technology Inc cxcr5
    a viSNE plots of B cells collected from non-inflamed and inflamed tonsils, HPV+ and HPV− HNSCC TIL and paired PBL (Supplementary Fig. ) were analyzed using Cytobank. Non-inflamed tonsil ( n = 4), inflamed tonsil ( n = 6), HPV + HNSCC ( n = 3), HPV− HNSCC ( n = 2). Bar plot displaying frequencies of GC B cells and plasma cells in non-inflamed tonsil ( n = 9), inflamed tonsil ( n = 16), HPV+ HNSCC ( n = 9), HPV− HNSCC ( n = 9). * P = 0.02 Student‘s 2-sided t test. b Bar plot for frequency of B cell subpopulations. Non-inflamed tonsil ( n = 9), inflamed tonsil ( n = 16), HPV+ HNSCC ( n = 12), HPV− HNSCC ( n = 13). ** P = 0.004, *** P = 0.0009, * P = 0.03, One way ANOVA followed by Tukey’s multiple comparisons test. c Frequencies of T follicular helper (T FH ), regulatory T follicular helper (T FHreg ), regulatory T cell (T reg ), T helper type 1 (T H 1) and CD8 T cells in non-inflamed tonsil ( n = 6), inflamed tonsils ( n = 10), HPV+ TIL ( n = 7), HPV− TIL ( n = 8). * P = 0.01,** P = 0.009,**** P < 0.0001. * P = 0.04, * P = 0.03, **** P < 0.0001. One-way ANOVA followed by Tukey’s multiple comparisons test. d Representative CD20+ IHC on HPV+ and HPV− HNSCC tumors (×4 magnification). e B cell infiltrate counted within tumor bed compared to TLS. Total numbers from n = 50, 25 HPV+, 25 HPV− were graphed. **** P < 0.0001, Student‘s 2-sided t test. f Tumor TLS by site within the oropharynx (tonsil vs. tongue). Total numbers from n = 50, 25 HPV+, 25 HPV− were graphed. ** P = 0.0096, Student‘s 2-sided. Data are presented as mean values ± SEM. g Total number of tumor TLS and non-tumor TLS numbers in HPV+ and HPV− disease. Total numbers from n = 50, 25 HPV+, 25 HPV− were graphed. * P = 0.0249, Student‘s 2-sided t test. Data are presented as mean values ± SEM. h Correlation of CD20 + tumor TLS with tumor area. Total tumor area (mm ) for each patient tumor was calculated by a pathologist. * P < 0.05, non-parametric Spearman correlation. i Total tumor TLS independently counted for CD20 + and CD4 + ( n = 50, 25 HPV+, 25 HPV−). **** P < 0.0001, *** P < 0.001, non-parametric Spearman correlation. j Total <t>CXCR5</t> was scored for all cell types ( n = 50, 25 HPV+, 25 HPV−).** P = 0.0012, Student‘s 2 sided t test. Source data are provided as a Source Data file.
    Cxcr5, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cxcr5/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cxcr5 - by Bioz Stars, 2024-05
    93/100 stars

    Images

    1) Product Images from "B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma"

    Article Title: B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma

    Journal: Nature Communications

    doi: 10.1038/s41467-021-23355-x

    a viSNE plots of B cells collected from non-inflamed and inflamed tonsils, HPV+ and HPV− HNSCC TIL and paired PBL (Supplementary Fig. ) were analyzed using Cytobank. Non-inflamed tonsil ( n = 4), inflamed tonsil ( n = 6), HPV + HNSCC ( n = 3), HPV− HNSCC ( n = 2). Bar plot displaying frequencies of GC B cells and plasma cells in non-inflamed tonsil ( n = 9), inflamed tonsil ( n = 16), HPV+ HNSCC ( n = 9), HPV− HNSCC ( n = 9). * P = 0.02 Student‘s 2-sided t test. b Bar plot for frequency of B cell subpopulations. Non-inflamed tonsil ( n = 9), inflamed tonsil ( n = 16), HPV+ HNSCC ( n = 12), HPV− HNSCC ( n = 13). ** P = 0.004, *** P = 0.0009, * P = 0.03, One way ANOVA followed by Tukey’s multiple comparisons test. c Frequencies of T follicular helper (T FH ), regulatory T follicular helper (T FHreg ), regulatory T cell (T reg ), T helper type 1 (T H 1) and CD8 T cells in non-inflamed tonsil ( n = 6), inflamed tonsils ( n = 10), HPV+ TIL ( n = 7), HPV− TIL ( n = 8). * P = 0.01,** P = 0.009,**** P < 0.0001. * P = 0.04, * P = 0.03, **** P < 0.0001. One-way ANOVA followed by Tukey’s multiple comparisons test. d Representative CD20+ IHC on HPV+ and HPV− HNSCC tumors (×4 magnification). e B cell infiltrate counted within tumor bed compared to TLS. Total numbers from n = 50, 25 HPV+, 25 HPV− were graphed. **** P < 0.0001, Student‘s 2-sided t test. f Tumor TLS by site within the oropharynx (tonsil vs. tongue). Total numbers from n = 50, 25 HPV+, 25 HPV− were graphed. ** P = 0.0096, Student‘s 2-sided. Data are presented as mean values ± SEM. g Total number of tumor TLS and non-tumor TLS numbers in HPV+ and HPV− disease. Total numbers from n = 50, 25 HPV+, 25 HPV− were graphed. * P = 0.0249, Student‘s 2-sided t test. Data are presented as mean values ± SEM. h Correlation of CD20 + tumor TLS with tumor area. Total tumor area (mm ) for each patient tumor was calculated by a pathologist. * P < 0.05, non-parametric Spearman correlation. i Total tumor TLS independently counted for CD20 + and CD4 + ( n = 50, 25 HPV+, 25 HPV−). **** P < 0.0001, *** P < 0.001, non-parametric Spearman correlation. j Total CXCR5 was scored for all cell types ( n = 50, 25 HPV+, 25 HPV−).** P = 0.0012, Student‘s 2 sided t test. Source data are provided as a Source Data file.
    Figure Legend Snippet: a viSNE plots of B cells collected from non-inflamed and inflamed tonsils, HPV+ and HPV− HNSCC TIL and paired PBL (Supplementary Fig. ) were analyzed using Cytobank. Non-inflamed tonsil ( n = 4), inflamed tonsil ( n = 6), HPV + HNSCC ( n = 3), HPV− HNSCC ( n = 2). Bar plot displaying frequencies of GC B cells and plasma cells in non-inflamed tonsil ( n = 9), inflamed tonsil ( n = 16), HPV+ HNSCC ( n = 9), HPV− HNSCC ( n = 9). * P = 0.02 Student‘s 2-sided t test. b Bar plot for frequency of B cell subpopulations. Non-inflamed tonsil ( n = 9), inflamed tonsil ( n = 16), HPV+ HNSCC ( n = 12), HPV− HNSCC ( n = 13). ** P = 0.004, *** P = 0.0009, * P = 0.03, One way ANOVA followed by Tukey’s multiple comparisons test. c Frequencies of T follicular helper (T FH ), regulatory T follicular helper (T FHreg ), regulatory T cell (T reg ), T helper type 1 (T H 1) and CD8 T cells in non-inflamed tonsil ( n = 6), inflamed tonsils ( n = 10), HPV+ TIL ( n = 7), HPV− TIL ( n = 8). * P = 0.01,** P = 0.009,**** P < 0.0001. * P = 0.04, * P = 0.03, **** P < 0.0001. One-way ANOVA followed by Tukey’s multiple comparisons test. d Representative CD20+ IHC on HPV+ and HPV− HNSCC tumors (×4 magnification). e B cell infiltrate counted within tumor bed compared to TLS. Total numbers from n = 50, 25 HPV+, 25 HPV− were graphed. **** P < 0.0001, Student‘s 2-sided t test. f Tumor TLS by site within the oropharynx (tonsil vs. tongue). Total numbers from n = 50, 25 HPV+, 25 HPV− were graphed. ** P = 0.0096, Student‘s 2-sided. Data are presented as mean values ± SEM. g Total number of tumor TLS and non-tumor TLS numbers in HPV+ and HPV− disease. Total numbers from n = 50, 25 HPV+, 25 HPV− were graphed. * P = 0.0249, Student‘s 2-sided t test. Data are presented as mean values ± SEM. h Correlation of CD20 + tumor TLS with tumor area. Total tumor area (mm ) for each patient tumor was calculated by a pathologist. * P < 0.05, non-parametric Spearman correlation. i Total tumor TLS independently counted for CD20 + and CD4 + ( n = 50, 25 HPV+, 25 HPV−). **** P < 0.0001, *** P < 0.001, non-parametric Spearman correlation. j Total CXCR5 was scored for all cell types ( n = 50, 25 HPV+, 25 HPV−).** P = 0.0012, Student‘s 2 sided t test. Source data are provided as a Source Data file.

    Techniques Used:

    anti cxcr5  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Cell Signaling Technology Inc anti cxcr5
    Tumor‐infiltrating CD20‐positive ICs, IGKC‐positive ICs, and CXCL13‐positive ICs, and follicular CD4‐positive ICs in the regional axillary lymph nodes in the high HER2‐AAb group and the low HER2‐AAb group. (A–F) Representative photographs of IHC staining for CD20 (A and B), IGKC (C and D), and CXCL13 (E and F) of the tumors with large cell counts (A, C and E) and the tumors with small cell counts (B, D and F). (G–J) Representative photographs of IHC staining for CD4 (brown) and <t>CXCR5</t> (red) of the regional axillary lymph nodes with large cell counts (G and I) and with small cell counts (H and J). Images (I) and (J) are the high power fields of the images (G) and (H), respectively. Original magnification, ×20 (A–H) and ×40 (I and J). (K–M) Counts of ICs positive for CD20 (K), IGKC (L), and CXCL13 (M) in the high HER2‐AAb group and the low HER2‐AAb group. (N) Counts of CD4‐positive ICs in CXCR5‐positive B‐cell follicles (follicular CD4 + ) of the regional axillary lymph nodes in the high HER2‐AAb group and the low HER2‐AAb group. Medians are shown by horizontal dotted lines. p , Mann–Whitney U test. Scale bar, 100 µm (A–H) and 50 µm (I and J)
    Anti Cxcr5, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cxcr5/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti cxcr5 - by Bioz Stars, 2024-05
    93/100 stars

    Images

    1) Product Images from "Enhanced humoral immunity in breast cancer patients with high serum concentration of anti‐HER2 autoantibody"

    Article Title: Enhanced humoral immunity in breast cancer patients with high serum concentration of anti‐HER2 autoantibody

    Journal: Cancer Medicine

    doi: 10.1002/cam4.3742

    Tumor‐infiltrating CD20‐positive ICs, IGKC‐positive ICs, and CXCL13‐positive ICs, and follicular CD4‐positive ICs in the regional axillary lymph nodes in the high HER2‐AAb group and the low HER2‐AAb group. (A–F) Representative photographs of IHC staining for CD20 (A and B), IGKC (C and D), and CXCL13 (E and F) of the tumors with large cell counts (A, C and E) and the tumors with small cell counts (B, D and F). (G–J) Representative photographs of IHC staining for CD4 (brown) and CXCR5 (red) of the regional axillary lymph nodes with large cell counts (G and I) and with small cell counts (H and J). Images (I) and (J) are the high power fields of the images (G) and (H), respectively. Original magnification, ×20 (A–H) and ×40 (I and J). (K–M) Counts of ICs positive for CD20 (K), IGKC (L), and CXCL13 (M) in the high HER2‐AAb group and the low HER2‐AAb group. (N) Counts of CD4‐positive ICs in CXCR5‐positive B‐cell follicles (follicular CD4 + ) of the regional axillary lymph nodes in the high HER2‐AAb group and the low HER2‐AAb group. Medians are shown by horizontal dotted lines. p , Mann–Whitney U test. Scale bar, 100 µm (A–H) and 50 µm (I and J)
    Figure Legend Snippet: Tumor‐infiltrating CD20‐positive ICs, IGKC‐positive ICs, and CXCL13‐positive ICs, and follicular CD4‐positive ICs in the regional axillary lymph nodes in the high HER2‐AAb group and the low HER2‐AAb group. (A–F) Representative photographs of IHC staining for CD20 (A and B), IGKC (C and D), and CXCL13 (E and F) of the tumors with large cell counts (A, C and E) and the tumors with small cell counts (B, D and F). (G–J) Representative photographs of IHC staining for CD4 (brown) and CXCR5 (red) of the regional axillary lymph nodes with large cell counts (G and I) and with small cell counts (H and J). Images (I) and (J) are the high power fields of the images (G) and (H), respectively. Original magnification, ×20 (A–H) and ×40 (I and J). (K–M) Counts of ICs positive for CD20 (K), IGKC (L), and CXCL13 (M) in the high HER2‐AAb group and the low HER2‐AAb group. (N) Counts of CD4‐positive ICs in CXCR5‐positive B‐cell follicles (follicular CD4 + ) of the regional axillary lymph nodes in the high HER2‐AAb group and the low HER2‐AAb group. Medians are shown by horizontal dotted lines. p , Mann–Whitney U test. Scale bar, 100 µm (A–H) and 50 µm (I and J)

    Techniques Used: Immunohistochemistry, MANN-WHITNEY

    cxcr5  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Cell Signaling Technology Inc cxcr5
    a . tSNE plots of all B cells collected HPV+ and HPV-HNSCC TIL and HNSCC PBMC analyzed using Cytofkit R program. HNSCC TIL (n=4), HNSCC PBMC (n=8). Cells are colored based on 5 populations identified using R phenograph. CD27, IgD, CD38, CXCR4, CD86, IgM surface markers were used to identify the 5 clusters. Bar plot showing frequencies of germinal center B cells and plasma cells in healthy tonsil (n=8), tonsillitis (n=9), HPV+ TIL(n=6), HPV-TIL (n=9). *P=0.02 Students 2-sided t test b . Bar plot showing the frequency of pre-germinal center B cells, naïve B cells, switched memory B cells and antibody secreting cells. c . Bar plot showing frequencies of Tfh, Tfhreg, Treg, Th1 and CD8 T cells in healthy tonsil (n=8), tonsillitis (n=10), HPV+ TIL (n= 5), HPV-TIL (n=7).*P=0.01,**P=0.004,****P<0.0001. One way ANOVA d . Representative CD20+ IHC on HPV (+) and HPV(-) HNSCC tumors from tonsil and tongue (4x magnification). e . B cells are predominantly contained within TLS compared to the tumor bed regardless of HPV status. Three areas of each patient section (n=50, 25 HPV+, 25 HPV-) were selected by the pathologist for countable B cell infiltrate in the tumor bed compared to a TLS (non GC or GC). The three areas for each patient were then averaged and subsequently graphed to reflect B cell infiltrate in the patient tumor compared to a TLS. ****P< 0.0001, Student’s 2-sided t test. f . Total number of tumor TLS are increased in HPV+ disease regardless of site. A HNSCC-specific pathologist identified TLS structures by organization of B cells via CD20 single-plex IHC in both patient tumor and non-tumor tissue. Enumeration of tumor TLS was parsed out by site of tumor within the oropharyngeal space (tonsil vs. tongue). Total numbers from n=50, 25 HPV+, 25 HPV(-) were graphed. **P< 0.01, Student’s 2-sided. g . Total number of tumor TLS are increased in HPV+ patients, however, non-tumor TLS numbers are equivalent in HPV+ and HPV- disease. Counting was done as described in ( f ). Total numbers from n=50, 25 HPV+, 25 HPV- were graphed. *P< 0.05, Student’s 2-sided t test. h . CD20 + and CD4 + TLS correlate in HPV+ and HPV-HNSCC patients. Total tumor TLS were independently counted for CD20 + and CD4 + by a HNSCC pathologist. Total numbers were tabulated and statistically compared (n=50, 25 HPV+, 25 HPV-). ****P< 0.0001, ***P< 0.001, non-parametric Spearman correlation. i . TLS-related marker, <t>CXCR5,</t> is increased in HPV+ HNSCC tumors. CXCR5 was scored by a HNSCC pathologist for the total percent expression of the markers across all cell types (n=50, 25 HPV+, 25 HPV-).***P< 0.001, **P< 0.001, Student’s 2 sided t test.
    Cxcr5, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cxcr5/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cxcr5 - by Bioz Stars, 2024-05
    93/100 stars

    Images

    1) Product Images from "Divergent cancer etiologies drive distinct B cell signatures and tertiary lymphoid structures"

    Article Title: Divergent cancer etiologies drive distinct B cell signatures and tertiary lymphoid structures

    Journal: bioRxiv

    doi: 10.1101/2020.05.29.123265

    a . tSNE plots of all B cells collected HPV+ and HPV-HNSCC TIL and HNSCC PBMC analyzed using Cytofkit R program. HNSCC TIL (n=4), HNSCC PBMC (n=8). Cells are colored based on 5 populations identified using R phenograph. CD27, IgD, CD38, CXCR4, CD86, IgM surface markers were used to identify the 5 clusters. Bar plot showing frequencies of germinal center B cells and plasma cells in healthy tonsil (n=8), tonsillitis (n=9), HPV+ TIL(n=6), HPV-TIL (n=9). *P=0.02 Students 2-sided t test b . Bar plot showing the frequency of pre-germinal center B cells, naïve B cells, switched memory B cells and antibody secreting cells. c . Bar plot showing frequencies of Tfh, Tfhreg, Treg, Th1 and CD8 T cells in healthy tonsil (n=8), tonsillitis (n=10), HPV+ TIL (n= 5), HPV-TIL (n=7).*P=0.01,**P=0.004,****P<0.0001. One way ANOVA d . Representative CD20+ IHC on HPV (+) and HPV(-) HNSCC tumors from tonsil and tongue (4x magnification). e . B cells are predominantly contained within TLS compared to the tumor bed regardless of HPV status. Three areas of each patient section (n=50, 25 HPV+, 25 HPV-) were selected by the pathologist for countable B cell infiltrate in the tumor bed compared to a TLS (non GC or GC). The three areas for each patient were then averaged and subsequently graphed to reflect B cell infiltrate in the patient tumor compared to a TLS. ****P< 0.0001, Student’s 2-sided t test. f . Total number of tumor TLS are increased in HPV+ disease regardless of site. A HNSCC-specific pathologist identified TLS structures by organization of B cells via CD20 single-plex IHC in both patient tumor and non-tumor tissue. Enumeration of tumor TLS was parsed out by site of tumor within the oropharyngeal space (tonsil vs. tongue). Total numbers from n=50, 25 HPV+, 25 HPV(-) were graphed. **P< 0.01, Student’s 2-sided. g . Total number of tumor TLS are increased in HPV+ patients, however, non-tumor TLS numbers are equivalent in HPV+ and HPV- disease. Counting was done as described in ( f ). Total numbers from n=50, 25 HPV+, 25 HPV- were graphed. *P< 0.05, Student’s 2-sided t test. h . CD20 + and CD4 + TLS correlate in HPV+ and HPV-HNSCC patients. Total tumor TLS were independently counted for CD20 + and CD4 + by a HNSCC pathologist. Total numbers were tabulated and statistically compared (n=50, 25 HPV+, 25 HPV-). ****P< 0.0001, ***P< 0.001, non-parametric Spearman correlation. i . TLS-related marker, CXCR5, is increased in HPV+ HNSCC tumors. CXCR5 was scored by a HNSCC pathologist for the total percent expression of the markers across all cell types (n=50, 25 HPV+, 25 HPV-).***P< 0.001, **P< 0.001, Student’s 2 sided t test.
    Figure Legend Snippet: a . tSNE plots of all B cells collected HPV+ and HPV-HNSCC TIL and HNSCC PBMC analyzed using Cytofkit R program. HNSCC TIL (n=4), HNSCC PBMC (n=8). Cells are colored based on 5 populations identified using R phenograph. CD27, IgD, CD38, CXCR4, CD86, IgM surface markers were used to identify the 5 clusters. Bar plot showing frequencies of germinal center B cells and plasma cells in healthy tonsil (n=8), tonsillitis (n=9), HPV+ TIL(n=6), HPV-TIL (n=9). *P=0.02 Students 2-sided t test b . Bar plot showing the frequency of pre-germinal center B cells, naïve B cells, switched memory B cells and antibody secreting cells. c . Bar plot showing frequencies of Tfh, Tfhreg, Treg, Th1 and CD8 T cells in healthy tonsil (n=8), tonsillitis (n=10), HPV+ TIL (n= 5), HPV-TIL (n=7).*P=0.01,**P=0.004,****P<0.0001. One way ANOVA d . Representative CD20+ IHC on HPV (+) and HPV(-) HNSCC tumors from tonsil and tongue (4x magnification). e . B cells are predominantly contained within TLS compared to the tumor bed regardless of HPV status. Three areas of each patient section (n=50, 25 HPV+, 25 HPV-) were selected by the pathologist for countable B cell infiltrate in the tumor bed compared to a TLS (non GC or GC). The three areas for each patient were then averaged and subsequently graphed to reflect B cell infiltrate in the patient tumor compared to a TLS. ****P< 0.0001, Student’s 2-sided t test. f . Total number of tumor TLS are increased in HPV+ disease regardless of site. A HNSCC-specific pathologist identified TLS structures by organization of B cells via CD20 single-plex IHC in both patient tumor and non-tumor tissue. Enumeration of tumor TLS was parsed out by site of tumor within the oropharyngeal space (tonsil vs. tongue). Total numbers from n=50, 25 HPV+, 25 HPV(-) were graphed. **P< 0.01, Student’s 2-sided. g . Total number of tumor TLS are increased in HPV+ patients, however, non-tumor TLS numbers are equivalent in HPV+ and HPV- disease. Counting was done as described in ( f ). Total numbers from n=50, 25 HPV+, 25 HPV- were graphed. *P< 0.05, Student’s 2-sided t test. h . CD20 + and CD4 + TLS correlate in HPV+ and HPV-HNSCC patients. Total tumor TLS were independently counted for CD20 + and CD4 + by a HNSCC pathologist. Total numbers were tabulated and statistically compared (n=50, 25 HPV+, 25 HPV-). ****P< 0.0001, ***P< 0.001, non-parametric Spearman correlation. i . TLS-related marker, CXCR5, is increased in HPV+ HNSCC tumors. CXCR5 was scored by a HNSCC pathologist for the total percent expression of the markers across all cell types (n=50, 25 HPV+, 25 HPV-).***P< 0.001, **P< 0.001, Student’s 2 sided t test.

    Techniques Used: Marker, Expressing

    culex quinquefasciatus 32 salivary mucin  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Cell Signaling Technology Inc culex quinquefasciatus 32 salivary mucin
    Culex Quinquefasciatus 32 Salivary Mucin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/culex quinquefasciatus 32 salivary mucin/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    culex quinquefasciatus 32 salivary mucin - by Bioz Stars, 2024-05
    93/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Cell Signaling Technology Inc rabbit anti cxcr5
    mRNA and protein expression of key genes and related receptors. (A) mRNA expression of CCL21, XCR1, CXCL13, CASR, and EDN1. (B) Protein expression of CCL21, CXCL13, and XCR1. (C) Protein expression of GPR174/CCR7 (the receptors of CCL21) and <t>CXCR5</t> (the receptors of CXCL13). n = 3–6. * p < 0.05, ** p < 0.01 vs. the sham group. I/R, ischemia reperfusion.
    Rabbit Anti Cxcr5, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti cxcr5/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti cxcr5 - by Bioz Stars, 2024-05
    93/100 stars
      Buy from Supplier

    93
    Cell Signaling Technology Inc 72172s

    72172s, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/72172s/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    72172s - by Bioz Stars, 2024-05
    93/100 stars
      Buy from Supplier

    93
    Cell Signaling Technology Inc rabbit anti cxcr5 monoclonal antibody
    TLS formation in MIA tumors (A) The schema of TLS formation. The first stage is B & T cell aggregation. The second stage is follicle formation with T-zone and B-zone. The third stage is ectopic germinal center formation with formation with follicular dendritic cell in light-zone. (B) Hierarchical clustering of Z score normalized gene expression of B cell infiltration markers (CD19 and CD20), follicle phenotype markers <t>(CXCR5</t> and CXCL13), and lymphocyte homing signal markers (CCR7 and CCL19). Color of the top bar represents tumor (red) or adjacent normal (blue) tissue. Correlations between expression levels from these six TLS markers and immune cell abundance corrected by tumor purity are shown in the right bar. p Values are calculated using Spearman correlation; ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05; ns p > 0.05. (C) Typical observation field of MIA six-plex TLS panel staining. The merged-channel multispectral image was captured after 5-cycle TSA staining and DAPI counterstain, revealing a classic lymphoid structure residing in MIA stromal tissue. Single channels are shown for the area bounded by the white rectangle. Fake colors are assigned as DAPI: blue, CD8: yellow, CXCR5: pink, CD4: green, CD20: red, CD35: cyan. Tfh cells are highlighted with white arrows (lower right corner images). (D–G) Paired comparisons of CD20 + B cell density, CD4 + T cell density (E), CD35 + follicle dendritic cell density (F), and CD8 + T cell density (G) between non-follicle (Non-Fol) and TLS areas
    Rabbit Anti Cxcr5 Monoclonal Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti cxcr5 monoclonal antibody/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti cxcr5 monoclonal antibody - by Bioz Stars, 2024-05
    93/100 stars
      Buy from Supplier

    93
    Cell Signaling Technology Inc cxcr5
    a The dot plot summarizing the cell–cell interactions among CD8-C2 (T RM -like), B, and CD4-C9 (T FH -like) cells by CellPhoneDB analysis. Only significant ligand–receptor interactions are presented here. The size of the circle indicates the statistical significance, and the color gradient indicates the mean expression value of gene pairs. b Representative multiplexed immunofluorescence (IF) of TLS-like lesion in EGFR-WT ( n = 14) (upper) (scale bar 100 μm: left, scale bars 50 μm: right magnified) and EGFR-MT ( n = 14) (lower) (scale bar 100 μm: left, scale bars 50 μm: right magnified) tumors. Summarized graph for the area of TLS-like lesions in EGFR-WT ( n = 5) and EGFR-MT ( n = 4) tumors for single-cell analysis (** p ≤ 0.005, two-sided test) (upper panel) and in EGFR-WT ( n = 9) and EGFR-MT ( n = 10) tumors from independent patients for validation (* p ≤ 0.05, two-sided test) (lower panel). c Representative multiplexed IF of CD4, CXCL13, CD103, CD8, <t>CXCR5,</t> and CD20 in tumor specimens from EGFR-WT ( n = 14) (left) (scale bar 100 μm) and EGFR-MT ( n = 14) (right) (scale bar 100 μm) patients. d Summarized graph for the numbers of each cell type in total TLS-like lesions in EGFR-WT ( n = 5) and EGFR-MT ( n = 4) patients. The number of CD4 + , CXCL13 + CD4 + T cells, CD8 + T cells, CD103 + CD8 + T cells are significantly higher in EGFR-WT than EGFR-MT (* p ≤ 0.05, ** p ≤ 0.005, two-sided test). e Summarized graph for the numbers of each cell type in total TLS-like lesions in EGFR-WT ( n = 9) and EGFR-MT ( n = 10) tumors from independent patients for validation. Consistently, the number of CD4 + , CXCL13 + CD4 + T cells, CD8 + T cells, CD103 + CD8 + T cells were significantly higher in EGFR-WT than EGFR-MT (** p ≤ 0.005, *** p ≤ 0.0005, two-sided test). f An illustrative summary of the proposed model for T FH –B–T RM lymphocyte cooperation in TLS for antitumor immunity in lung cancer. Data are represented as mean ± SEM. Source data are provided as a Source Data file.
    Cxcr5, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cxcr5/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cxcr5 - by Bioz Stars, 2024-05
    93/100 stars
      Buy from Supplier

    93
    Cell Signaling Technology Inc anti cxcr5
    Tumor‐infiltrating CD20‐positive ICs, IGKC‐positive ICs, and CXCL13‐positive ICs, and follicular CD4‐positive ICs in the regional axillary lymph nodes in the high HER2‐AAb group and the low HER2‐AAb group. (A–F) Representative photographs of IHC staining for CD20 (A and B), IGKC (C and D), and CXCL13 (E and F) of the tumors with large cell counts (A, C and E) and the tumors with small cell counts (B, D and F). (G–J) Representative photographs of IHC staining for CD4 (brown) and <t>CXCR5</t> (red) of the regional axillary lymph nodes with large cell counts (G and I) and with small cell counts (H and J). Images (I) and (J) are the high power fields of the images (G) and (H), respectively. Original magnification, ×20 (A–H) and ×40 (I and J). (K–M) Counts of ICs positive for CD20 (K), IGKC (L), and CXCL13 (M) in the high HER2‐AAb group and the low HER2‐AAb group. (N) Counts of CD4‐positive ICs in CXCR5‐positive B‐cell follicles (follicular CD4 + ) of the regional axillary lymph nodes in the high HER2‐AAb group and the low HER2‐AAb group. Medians are shown by horizontal dotted lines. p , Mann–Whitney U test. Scale bar, 100 µm (A–H) and 50 µm (I and J)
    Anti Cxcr5, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cxcr5/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti cxcr5 - by Bioz Stars, 2024-05
    93/100 stars
      Buy from Supplier

    93
    Cell Signaling Technology Inc culex quinquefasciatus 32 salivary mucin
    Tumor‐infiltrating CD20‐positive ICs, IGKC‐positive ICs, and CXCL13‐positive ICs, and follicular CD4‐positive ICs in the regional axillary lymph nodes in the high HER2‐AAb group and the low HER2‐AAb group. (A–F) Representative photographs of IHC staining for CD20 (A and B), IGKC (C and D), and CXCL13 (E and F) of the tumors with large cell counts (A, C and E) and the tumors with small cell counts (B, D and F). (G–J) Representative photographs of IHC staining for CD4 (brown) and <t>CXCR5</t> (red) of the regional axillary lymph nodes with large cell counts (G and I) and with small cell counts (H and J). Images (I) and (J) are the high power fields of the images (G) and (H), respectively. Original magnification, ×20 (A–H) and ×40 (I and J). (K–M) Counts of ICs positive for CD20 (K), IGKC (L), and CXCL13 (M) in the high HER2‐AAb group and the low HER2‐AAb group. (N) Counts of CD4‐positive ICs in CXCR5‐positive B‐cell follicles (follicular CD4 + ) of the regional axillary lymph nodes in the high HER2‐AAb group and the low HER2‐AAb group. Medians are shown by horizontal dotted lines. p , Mann–Whitney U test. Scale bar, 100 µm (A–H) and 50 µm (I and J)
    Culex Quinquefasciatus 32 Salivary Mucin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/culex quinquefasciatus 32 salivary mucin/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    culex quinquefasciatus 32 salivary mucin - by Bioz Stars, 2024-05
    93/100 stars
      Buy from Supplier

    Image Search Results


    mRNA and protein expression of key genes and related receptors. (A) mRNA expression of CCL21, XCR1, CXCL13, CASR, and EDN1. (B) Protein expression of CCL21, CXCL13, and XCR1. (C) Protein expression of GPR174/CCR7 (the receptors of CCL21) and CXCR5 (the receptors of CXCL13). n = 3–6. * p < 0.05, ** p < 0.01 vs. the sham group. I/R, ischemia reperfusion.

    Journal: Frontiers in Genetics

    Article Title: Activation of CCL21-GPR174/CCR7 on cardiac fibroblasts underlies myocardial ischemia/reperfusion injury

    doi: 10.3389/fgene.2022.946524

    Figure Lengend Snippet: mRNA and protein expression of key genes and related receptors. (A) mRNA expression of CCL21, XCR1, CXCL13, CASR, and EDN1. (B) Protein expression of CCL21, CXCL13, and XCR1. (C) Protein expression of GPR174/CCR7 (the receptors of CCL21) and CXCR5 (the receptors of CXCL13). n = 3–6. * p < 0.05, ** p < 0.01 vs. the sham group. I/R, ischemia reperfusion.

    Article Snippet: The primary antibodies were as follows: goat anti-CCL21 (1:1000; R&D Systems, Minneapolis, MN), rabbit anti-XCR1 (1:1000; Novus Biologicals, Littleton, CO), goat anti-CXCL13 (1:1000; R&D Systems, Minneapolis, MN), goat anti-CCR7 (1:1000; Novus Biologicals, Littleton, CO), rabbit anti-GPR174 (1:1000; Biorbyt, Cambridge, United Kingdom), rabbit anti-CXCR5 (1:1000; Absin, Shanghai, China), and rabbit anti-β-tubulin (1:5000; Cell Signaling Technology, Beverly, MA).

    Techniques: Expressing

    Journal: iScience

    Article Title: Tertiary lymphoid structure and decreased CD8 + T cell infiltration in minimally invasive adenocarcinoma

    doi: 10.1016/j.isci.2022.103883

    Figure Lengend Snippet:

    Article Snippet: Rabbit anti-CXCR5 monoclonal antibody (D6L3C) , CST , Cat#: 72172S.

    Techniques: Recombinant, Software

    TLS formation in MIA tumors (A) The schema of TLS formation. The first stage is B & T cell aggregation. The second stage is follicle formation with T-zone and B-zone. The third stage is ectopic germinal center formation with formation with follicular dendritic cell in light-zone. (B) Hierarchical clustering of Z score normalized gene expression of B cell infiltration markers (CD19 and CD20), follicle phenotype markers (CXCR5 and CXCL13), and lymphocyte homing signal markers (CCR7 and CCL19). Color of the top bar represents tumor (red) or adjacent normal (blue) tissue. Correlations between expression levels from these six TLS markers and immune cell abundance corrected by tumor purity are shown in the right bar. p Values are calculated using Spearman correlation; ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05; ns p > 0.05. (C) Typical observation field of MIA six-plex TLS panel staining. The merged-channel multispectral image was captured after 5-cycle TSA staining and DAPI counterstain, revealing a classic lymphoid structure residing in MIA stromal tissue. Single channels are shown for the area bounded by the white rectangle. Fake colors are assigned as DAPI: blue, CD8: yellow, CXCR5: pink, CD4: green, CD20: red, CD35: cyan. Tfh cells are highlighted with white arrows (lower right corner images). (D–G) Paired comparisons of CD20 + B cell density, CD4 + T cell density (E), CD35 + follicle dendritic cell density (F), and CD8 + T cell density (G) between non-follicle (Non-Fol) and TLS areas

    Journal: iScience

    Article Title: Tertiary lymphoid structure and decreased CD8 + T cell infiltration in minimally invasive adenocarcinoma

    doi: 10.1016/j.isci.2022.103883

    Figure Lengend Snippet: TLS formation in MIA tumors (A) The schema of TLS formation. The first stage is B & T cell aggregation. The second stage is follicle formation with T-zone and B-zone. The third stage is ectopic germinal center formation with formation with follicular dendritic cell in light-zone. (B) Hierarchical clustering of Z score normalized gene expression of B cell infiltration markers (CD19 and CD20), follicle phenotype markers (CXCR5 and CXCL13), and lymphocyte homing signal markers (CCR7 and CCL19). Color of the top bar represents tumor (red) or adjacent normal (blue) tissue. Correlations between expression levels from these six TLS markers and immune cell abundance corrected by tumor purity are shown in the right bar. p Values are calculated using Spearman correlation; ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05; ns p > 0.05. (C) Typical observation field of MIA six-plex TLS panel staining. The merged-channel multispectral image was captured after 5-cycle TSA staining and DAPI counterstain, revealing a classic lymphoid structure residing in MIA stromal tissue. Single channels are shown for the area bounded by the white rectangle. Fake colors are assigned as DAPI: blue, CD8: yellow, CXCR5: pink, CD4: green, CD20: red, CD35: cyan. Tfh cells are highlighted with white arrows (lower right corner images). (D–G) Paired comparisons of CD20 + B cell density, CD4 + T cell density (E), CD35 + follicle dendritic cell density (F), and CD8 + T cell density (G) between non-follicle (Non-Fol) and TLS areas

    Article Snippet: Rabbit anti-CXCR5 monoclonal antibody (D6L3C) , CST , Cat#: 72172S.

    Techniques: Expressing, Staining

    Treg recruitment as potential mechanism of decreased CD8 + T cell infiltration in tertiary lymphoid structures (A) Comparison of immune suppressive cell infiltration estimated from XCELL between MIA tumor and adjacent normal tissues. p values are calculated using Mann-Whitney U test; ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05; ns p > 0.05. (B) Plot of Tfr/Tfh marker ratio vs CD8 + T cell infiltration. FoxP3, PDCD1, and IL2RA are markers of Tfr cells, while BCL6, ICOS, and IL7R are markers of Tfh cells. See text. p values are calculated using Spearman correlation test; ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05; ns p > 0.05. (C) Typical observation field of MIA 7-plex panel staining for Tfr and Tfh. Merged multispectral image was captured after 6-cycle TSA staining and DAPI counterstain and reveals a mature TLS architecture. Single channels are shown for the area bounded by the white rectangle. Fake colors are assigned as DAPI: blue, CD8: yellow, CXCR5: pink, CD4: green, FOXP3: red, BCL6: cyan and CD3: orange. Sub-populations of CD4 + T cells are highlighted by arrows (Tfr: red, Treg: purple, Th: green and Tfh: cyan). (D) Paired comparison of CD8 + T cell density between non-follicle (Non-Fol) and TLS areas. (E) Paired comparison of ratio of regulatory T cells to helper T cells between TLS and non-follicle areas. (F) Comparison of CD8 + T cell density between groups with high and low Tfr/Tfh ratio

    Journal: iScience

    Article Title: Tertiary lymphoid structure and decreased CD8 + T cell infiltration in minimally invasive adenocarcinoma

    doi: 10.1016/j.isci.2022.103883

    Figure Lengend Snippet: Treg recruitment as potential mechanism of decreased CD8 + T cell infiltration in tertiary lymphoid structures (A) Comparison of immune suppressive cell infiltration estimated from XCELL between MIA tumor and adjacent normal tissues. p values are calculated using Mann-Whitney U test; ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05; ns p > 0.05. (B) Plot of Tfr/Tfh marker ratio vs CD8 + T cell infiltration. FoxP3, PDCD1, and IL2RA are markers of Tfr cells, while BCL6, ICOS, and IL7R are markers of Tfh cells. See text. p values are calculated using Spearman correlation test; ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05; ns p > 0.05. (C) Typical observation field of MIA 7-plex panel staining for Tfr and Tfh. Merged multispectral image was captured after 6-cycle TSA staining and DAPI counterstain and reveals a mature TLS architecture. Single channels are shown for the area bounded by the white rectangle. Fake colors are assigned as DAPI: blue, CD8: yellow, CXCR5: pink, CD4: green, FOXP3: red, BCL6: cyan and CD3: orange. Sub-populations of CD4 + T cells are highlighted by arrows (Tfr: red, Treg: purple, Th: green and Tfh: cyan). (D) Paired comparison of CD8 + T cell density between non-follicle (Non-Fol) and TLS areas. (E) Paired comparison of ratio of regulatory T cells to helper T cells between TLS and non-follicle areas. (F) Comparison of CD8 + T cell density between groups with high and low Tfr/Tfh ratio

    Article Snippet: Rabbit anti-CXCR5 monoclonal antibody (D6L3C) , CST , Cat#: 72172S.

    Techniques: MANN-WHITNEY, Marker, Staining

    Journal: iScience

    Article Title: Tertiary lymphoid structure and decreased CD8 + T cell infiltration in minimally invasive adenocarcinoma

    doi: 10.1016/j.isci.2022.103883

    Figure Lengend Snippet:

    Article Snippet: Rabbit anti-CXCR5 monoclonal antibody (D6L3C) , CST , Cat#: 72172S.

    Techniques: Recombinant, Software

    a The dot plot summarizing the cell–cell interactions among CD8-C2 (T RM -like), B, and CD4-C9 (T FH -like) cells by CellPhoneDB analysis. Only significant ligand–receptor interactions are presented here. The size of the circle indicates the statistical significance, and the color gradient indicates the mean expression value of gene pairs. b Representative multiplexed immunofluorescence (IF) of TLS-like lesion in EGFR-WT ( n = 14) (upper) (scale bar 100 μm: left, scale bars 50 μm: right magnified) and EGFR-MT ( n = 14) (lower) (scale bar 100 μm: left, scale bars 50 μm: right magnified) tumors. Summarized graph for the area of TLS-like lesions in EGFR-WT ( n = 5) and EGFR-MT ( n = 4) tumors for single-cell analysis (** p ≤ 0.005, two-sided test) (upper panel) and in EGFR-WT ( n = 9) and EGFR-MT ( n = 10) tumors from independent patients for validation (* p ≤ 0.05, two-sided test) (lower panel). c Representative multiplexed IF of CD4, CXCL13, CD103, CD8, CXCR5, and CD20 in tumor specimens from EGFR-WT ( n = 14) (left) (scale bar 100 μm) and EGFR-MT ( n = 14) (right) (scale bar 100 μm) patients. d Summarized graph for the numbers of each cell type in total TLS-like lesions in EGFR-WT ( n = 5) and EGFR-MT ( n = 4) patients. The number of CD4 + , CXCL13 + CD4 + T cells, CD8 + T cells, CD103 + CD8 + T cells are significantly higher in EGFR-WT than EGFR-MT (* p ≤ 0.05, ** p ≤ 0.005, two-sided test). e Summarized graph for the numbers of each cell type in total TLS-like lesions in EGFR-WT ( n = 9) and EGFR-MT ( n = 10) tumors from independent patients for validation. Consistently, the number of CD4 + , CXCL13 + CD4 + T cells, CD8 + T cells, CD103 + CD8 + T cells were significantly higher in EGFR-WT than EGFR-MT (** p ≤ 0.005, *** p ≤ 0.0005, two-sided test). f An illustrative summary of the proposed model for T FH –B–T RM lymphocyte cooperation in TLS for antitumor immunity in lung cancer. Data are represented as mean ± SEM. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Dysregulation of T FH -B-T RM lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR -mutant lung cancer

    doi: 10.1038/s41467-021-26362-0

    Figure Lengend Snippet: a The dot plot summarizing the cell–cell interactions among CD8-C2 (T RM -like), B, and CD4-C9 (T FH -like) cells by CellPhoneDB analysis. Only significant ligand–receptor interactions are presented here. The size of the circle indicates the statistical significance, and the color gradient indicates the mean expression value of gene pairs. b Representative multiplexed immunofluorescence (IF) of TLS-like lesion in EGFR-WT ( n = 14) (upper) (scale bar 100 μm: left, scale bars 50 μm: right magnified) and EGFR-MT ( n = 14) (lower) (scale bar 100 μm: left, scale bars 50 μm: right magnified) tumors. Summarized graph for the area of TLS-like lesions in EGFR-WT ( n = 5) and EGFR-MT ( n = 4) tumors for single-cell analysis (** p ≤ 0.005, two-sided test) (upper panel) and in EGFR-WT ( n = 9) and EGFR-MT ( n = 10) tumors from independent patients for validation (* p ≤ 0.05, two-sided test) (lower panel). c Representative multiplexed IF of CD4, CXCL13, CD103, CD8, CXCR5, and CD20 in tumor specimens from EGFR-WT ( n = 14) (left) (scale bar 100 μm) and EGFR-MT ( n = 14) (right) (scale bar 100 μm) patients. d Summarized graph for the numbers of each cell type in total TLS-like lesions in EGFR-WT ( n = 5) and EGFR-MT ( n = 4) patients. The number of CD4 + , CXCL13 + CD4 + T cells, CD8 + T cells, CD103 + CD8 + T cells are significantly higher in EGFR-WT than EGFR-MT (* p ≤ 0.05, ** p ≤ 0.005, two-sided test). e Summarized graph for the numbers of each cell type in total TLS-like lesions in EGFR-WT ( n = 9) and EGFR-MT ( n = 10) tumors from independent patients for validation. Consistently, the number of CD4 + , CXCL13 + CD4 + T cells, CD8 + T cells, CD103 + CD8 + T cells were significantly higher in EGFR-WT than EGFR-MT (** p ≤ 0.005, *** p ≤ 0.0005, two-sided test). f An illustrative summary of the proposed model for T FH –B–T RM lymphocyte cooperation in TLS for antitumor immunity in lung cancer. Data are represented as mean ± SEM. Source data are provided as a Source Data file.

    Article Snippet: To evaluate the CXCL13 + CD4, CXCR5 + CD20, CD103 + CD8, we performed another set of multiplexed IF using primary antibodies against the following antigens: for CD4 (ab133616, Abcam, Cambridge, UK, 1:200), CD8 (MCA1817, Bio-Rad, Hercules, CA, USA, 1:300), CXCL13 (PA5-47035, Invitrogen, Massachusetts, USA, 1:40), CXCR5 (72172 S, Cell Signaling Technology, Massachusetts, USA, 1:200), CD20 (ab9475, Abcam, Cambridge, UK, 1:100), and CD103 (ab129202, Abcam, Cambridge, UK, 1:500).

    Techniques: Expressing, Immunofluorescence, Single-cell Analysis

    Tumor‐infiltrating CD20‐positive ICs, IGKC‐positive ICs, and CXCL13‐positive ICs, and follicular CD4‐positive ICs in the regional axillary lymph nodes in the high HER2‐AAb group and the low HER2‐AAb group. (A–F) Representative photographs of IHC staining for CD20 (A and B), IGKC (C and D), and CXCL13 (E and F) of the tumors with large cell counts (A, C and E) and the tumors with small cell counts (B, D and F). (G–J) Representative photographs of IHC staining for CD4 (brown) and CXCR5 (red) of the regional axillary lymph nodes with large cell counts (G and I) and with small cell counts (H and J). Images (I) and (J) are the high power fields of the images (G) and (H), respectively. Original magnification, ×20 (A–H) and ×40 (I and J). (K–M) Counts of ICs positive for CD20 (K), IGKC (L), and CXCL13 (M) in the high HER2‐AAb group and the low HER2‐AAb group. (N) Counts of CD4‐positive ICs in CXCR5‐positive B‐cell follicles (follicular CD4 + ) of the regional axillary lymph nodes in the high HER2‐AAb group and the low HER2‐AAb group. Medians are shown by horizontal dotted lines. p , Mann–Whitney U test. Scale bar, 100 µm (A–H) and 50 µm (I and J)

    Journal: Cancer Medicine

    Article Title: Enhanced humoral immunity in breast cancer patients with high serum concentration of anti‐HER2 autoantibody

    doi: 10.1002/cam4.3742

    Figure Lengend Snippet: Tumor‐infiltrating CD20‐positive ICs, IGKC‐positive ICs, and CXCL13‐positive ICs, and follicular CD4‐positive ICs in the regional axillary lymph nodes in the high HER2‐AAb group and the low HER2‐AAb group. (A–F) Representative photographs of IHC staining for CD20 (A and B), IGKC (C and D), and CXCL13 (E and F) of the tumors with large cell counts (A, C and E) and the tumors with small cell counts (B, D and F). (G–J) Representative photographs of IHC staining for CD4 (brown) and CXCR5 (red) of the regional axillary lymph nodes with large cell counts (G and I) and with small cell counts (H and J). Images (I) and (J) are the high power fields of the images (G) and (H), respectively. Original magnification, ×20 (A–H) and ×40 (I and J). (K–M) Counts of ICs positive for CD20 (K), IGKC (L), and CXCL13 (M) in the high HER2‐AAb group and the low HER2‐AAb group. (N) Counts of CD4‐positive ICs in CXCR5‐positive B‐cell follicles (follicular CD4 + ) of the regional axillary lymph nodes in the high HER2‐AAb group and the low HER2‐AAb group. Medians are shown by horizontal dotted lines. p , Mann–Whitney U test. Scale bar, 100 µm (A–H) and 50 µm (I and J)

    Article Snippet: The following primary antibodies were used: polyclonal anti‐Kappa Light Chain (1:200, Invitrogen), anti‐CD20 (L26, 1:50, Abcam), anti‐HLA Class 1 ABC (EMR8‐5, 1:100, Abcam), anti‐CD8 (C8/144B, 1:100, Dako), anti‐FOXP3 (236A/E7, 1:100, Abcam), anti‐CXCR5 (D6L3C, 1:200, Cell Signaling Technology), anti‐CD4 (4B12, 1:80, Dako), polyclonal anti‐CXCL13 (1:100, Invitrogen), and SP142‐compatible anti‐PD‐L1 (28‐8, 1:400, Abcam).

    Techniques: Immunohistochemistry, MANN-WHITNEY